Oncolytics Biotech (ONCY) Announces Abstract Outlining Potential New Biomarker to be Presented at the 2020 Gastrointestinal Cancers Symposium

Oncolytics Biotech Inc. (NASDAQ: ONCY), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the acceptance of an abstract highlighting new biomarker data from the randomized study NCI 8601: Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer. The data will be part of a poster presentation at the 2020 Gastrointestinal Cancers Symposium sponsored by ASCO, January 23 - 25, 2019, in San Francisco.

The abstract, CEACAM6 is a candidate biomarker for Reolysin (pelareorep) sensitivity in pancreatic adenocarcinoma (PDAC), was co-authored by Dr. Anne Noonan, Department of Medical Oncology, Ohio State University Wexner Medical Center, Richard Solove Research Institute and James Cancer Hospital, and Dr. Tanios Bekaii-Saab Senior Associate Consultant, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona.

Abstracts will be published at 5:00 pm ET on Tuesday, January 21, 2020 on the ASCO meeting library website at https://meetinglibrary.asco.org/.

Abstract ID: 285103
Abstract Number: 746
Poster Board: M13
Abstract Title: CEACAM6 as a candidate biomarker for pelareorep sensitivity in pancreatic adenocarcinoma (PDAC)
Session Information: Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Session Date & Time: January 24, 2020 from 12:00 PM-1:30 PM & 4:30 PM-5:30 PM

You May Also Be Interested In

• Morgan Stanley CEO: investment banking momentum is building - Conference Call
• enVVeno Medical (NVNO) Reports New Topline Efficacy Data from VenoValve Trial
• Turnstone Biologics Corp (TSBX) Announces Resignation of Patrick Machado from Board